Inflammatory Receptors/Ligands as a Novel Target Against Obesity-Induced Inflammation and Metabolic Diseases

Rina Yu

Article

Korean J Obes 2014; 23(2): 83-90

Published online June 30, 2014

Inflammatory Receptors/Ligands as a Novel Target Against Obesity-Induced Inflammation and Metabolic Diseases

Rina Yu

Author Affiliations

Department of Food Science and Nutrition, University of Ulsan, Ulsan, KoreaObesity-induced inflammation is considered to be a potential cause of metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular
diseases. Various inflammatory components involved in obesity-induced inflammation are known, but the biomolecules and
mechanisms underlying the obesity-related inflammation/metabolic diseases remain to be elucidated. Cell surface membrane receptors
TNFRSFs (Tumor Necrosis Factor Receptor Superfamily) and their counterpart ligands provide important inflammatory signals through their
interaction, and thus have been exploited for therapeutic targets for treating various inflammatory diseases. Recent studies demonstrate that
some of the inflammatory receptors/ligands are associated with obesity-induced inflammation and metabolic diseases. In this mini-review, the
role of four different inflammatory receptors/ligand (CD40/CD40L, 4-1BB/4-BBL, FN14/TWEAK, HEVM/LIGHT) interactions are discussed
along with their potential for therapeutic targets against obesity-related inflammation and metabolic diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Go to

Abstract
References

Obesity-induced inflammation is considered to be a potential cause of metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular diseases. Various inflammatory components involved in obesity-induced inflammation are known, but the biomolecules and mechanisms underlying the obesity-related inflammation/metabolic diseases remain to be elucidated. Cell surface membrane receptors TNFRSFs (Tumor Necrosis Factor Receptor Superfamily) and their counterpart ligands provide important inflammatory signals through their interaction, and thus have been exploited for therapeutic targets for treating various inflammatory diseases. Recent studies demonstrate that some of the inflammatory receptors/ligands are associated with obesity-induced inflammation and metabolic diseases. In this mini-review, the role of four different inflammatory receptors/ligand (CD40/CD40L, 4-1BB/4-BBL, FN14/TWEAK, HEVM/LIGHT) interactions are discussed along with their potential for therapeutic targets against obesity-related inflammation and metabolic diseases.

Keywords: Obesity, Inflammation, Metabolic diseases, Inflammatory receptor/ligand

References

Go to

Abstract
References

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
Wellen KE, Hotamisligil GS. Inflammation, stress, diabetes. J Clin Invest 2005;115:1111-9.
Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7.
Yu R, Kim CS, Kang JH. Inflammatory components of adipose tissue as target for treatment of metabolic syndrome. Forum Nutr 2009;61:95-103.
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415-45.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
Kim CS, Lee SC, Kim YM, Kim BS, Choi HS, Kawada T, et al. Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice. Obesity (Silver Spring) 2008;16:1261-9.
Yu R, Kim CS, Kwon BS, Kawada T. Mesenteric adipose tissuederived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity (Silver Spring) 2006;14:1353-62.
Maym?-Masip E, Fern?ndez-Veledo S, Garcia Espa?a A, V?zquezCarballo A, Tinahones FJ, Garc?a-Fuentes E, et al. The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα. J Clin Endocrinol Metab 2013;98:E1323-33.
Tu TH, Kim CS, Goto T, Kawada T, Kim BS, Yu R. 4-1BB/4-1BBL interaction promotes obesity-induced adipose inflammation by triggering bidirectional inflammatory signaling in adipocytes/macrophages. Mediators Inflamm 2012;2012:972629.
Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-85.
Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013;12:147-68.
Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol 2009;647:8-36.
Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009;21:293-300.
Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010;116:4317-27.
Poggi M, Jager J, Paulmyer-Lacroix O, Peiretti F, Gremeaux T, Verdier M, et al. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia 2009;52:1152-63.
Missiou A, Wolf D, Platzer I, Ernst S, Walter C, Rudolf P, et al. CD40L induces inflammation and adipogenesis in adipose cells-a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010;103:788-96.
Poggi M, Engel D, Christ A, Beckers L, Wijnands E, Boon L, et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler Thromb Vasc Biol 2011;31:2251-60.
Wolf D, Jehle F, Ortiz Rodriguez A, Dufner B, Hoppe N, Colberg C, et al. CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-antibodies. PLoS One 2014;7:e33026.
Guo CA, Kogan S, Amano SU, Wang M, Dagdeviren S, Friedline RH, et al. CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, insulin resistance. Am J Physiol Endocrinol Metab 2013;304:E951-63.
Bukczynski J, Wen T, Wang C, Christie N, Routy JP, Boulassel MR, et al. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol 2005;175:6378-89.
Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009;229:192-215.
Schwarz H. Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol 2005;77:281-6.
Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012;11:1062-70.
Ju SA, Cheon SH, Park SM, Tam NQ, Kim YM, An WG, et al. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int J Cancer 2008;122:2784-90.
Arribillaga L, Sarobe P, Arina A, Gorraiz M, Borr?s-Cuesta F, Ruiz J, et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005;23:3493-9.
Lee SW, Croft M. 4-1BB as a therapeutic target for human disease. Adv Exp Med Biol 2009;647:120-9.
Olofsson PS, S?derstr?m LA, W?gs?ter D, Sheikine Y, Ocaya P, Lang F, et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008;117:1292-301.
Jeon HJ, Choi JH, Jung IH, Park JG, Lee MR, Lee MN, et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010;121:1124-33.
Kim CS, Kim JG, Lee BJ, Choi MS, Choi HS, Kawada T, et al. Deficiency for costimulatory receptor 4-1BB protects against obesityinduced inflammation and metabolic disorders. Diabetes 2011;60:3159-68.
Kim CS, Tu TH, Kawada T, Kim BS, Yu R. The immune signaling molecule 4-1BB stimulation reduces adiposity, insulin resistance, hepatosteatosis in obese mice. Endocrinology 2010;151:472535.
Yu R. Response to Comment on: Kim, et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-68. Diabetes 2012;61:e7.
Tu TH, Kim CS, Kang JH, Nam-Goong IS, Nam CW, Kim ES, et al. Levels of 4-1BB transcripts and soluble 4-1BB protein are elevated in the adipose tissue of human obese subjects and are associated with inflammatory and metabolic parameters. Int J Obes (Lond) 2014 [Epub ahead of print].
Kwon BS, Hurtado JC, Lee ZH, Kwack KB, Seo SK, Choi BK, et al. Immune responses in 4-1BB (CD137)-deficient mice. J Immunol 2002;168:5483-90.
Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, induction of lymphopenia, anemia, thrombocytopenia in anti-CD137-treated mice. J Immunol 2007;178:4194-213.
Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011;244:99-114.
Michaelson JS, Wisniacki N, Burkly LC, Putterman C. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun 2012;39:130-42.
Vendrell J, Maym?-Masip E, Tinahones F, Garc?a-Espa?a A, Megia A, Caubet E, et al. Tumor necrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia. J Clin Endocrinol Metab 2010;95:2983-92.
Vendrell J, Chac?n MR. TWEAK: a new player in obesity and diabetes. Front Immunol 2013;4:488.
Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009;11:1050-6.
Blanco-Colio LM. TWEAK/Fn14 Axis: a promising target for the treatment of cardiovascular diseases. Front Immunol 2014;5:3.
Blanco-Colio LM, Mart?n-Ventura JL, Mu??z-Garc?a B, Orbe J, P?ramo JA, Michel JB, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:916-22.
Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, L?ssner U, Bl?her M, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008;199:440-4.
Maym?-Masip E, Fern?ndez-Veledo S, Garcia Espa?a A, V?zquezCarballo A, Tinahones FJ, Garc?a-Fuentes E, et al. The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα. J Clin Endocrinol Metab 2013;98:E1323-33.
Carrero JJ, Ortiz A, Qureshi AR, Mart?n-Ventura JL, B?r?ny P, Heimb?rger O, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110-8.
Yilmaz MI, Carrero JJ, Ortiz A, Mart?n-Ventura JL, Sonmez A, Saglam M, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1716-23.
Shui JW, Steinberg MW, Kronenberg M. Regulation of inflammation, autoimmunity, infection immunity by HVEM-BTLA signaling. J Leukoc Biol 2011;89:517-23.
Pierer M, Brentano F, Rethage J, Wagner U, Hantzschel H, Gay RE, et al. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1063-70.
Kang YM, Kim SY, Kang JH, Han SW, Nam EJ, Kyung HS, et al. LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes. Arthritis Rheum 2007;56:1106-17.
Croft M, Duan W, Choi H, Eun SY, Madireddi S, Mehta A. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 2012;33:144-52.
Heo SK, Ju SA, Lee SC, Park SM, Choe SY, Kwon B, et al. LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM. J Leukoc Biol 2006;79:330-8.
Sandberg WJ, Halvorsen B, Yndestad A, Smith C, Otterdal K, Brosstad FR, et al. Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis. Circ Res 2009;104:60-8.
An MM, Fan KX, Cao YB, Shen H, Zhang JD, Lu L, et al. Lymphtoxin beta receptor-Ig protects from T-cell-mediated liver injury in mice through blocking LIGHT/HVEM signaling. Biol Pharm Bull 2006;29:2025-30.
Kim HM, Jeong CS, Choi HS, Kawada T, Yu R. LIGHT/TNFSF14 enhances adipose tissue inflammatory responses through its interaction with HVEM. FEBS Lett 2011;585:579-84.
Kim HJ, Kim HM, Kim CS, Jeong CS, Choi HS, Kawada T, et al. HVEM-deficient mice fed a high-fat diet are protected from adipose tissue inflammation and glucose intolerance. FEBS Lett 2011;585:2285-90.
Bassols J, Moreno-Navarrete JM, Ortega F, Ricart W, FernandezReal JM. LIGHT is associated with hypertriglyceridemia in obese subjects and increased cytokine secretion from cultured human adipocytes. Int J Obes (Lond) 2010;34:146-56.
Bassols J, Moreno JM, Ortega F, Ricart W, Fernandez-Real JM. Characterization of herpes virus entry mediator as a factor linked to obesity. Obesity (Silver Spring) 2010;18:239-46.